[1] Boulle F,Kenis G,Cazorla M,et al. TrkB inhibition as a therapeutic target for CNS-related disorders[J]. Prog Neurobiol,2012,98(2): 197-206.[2] Scala S,Wosikowski K,Giannakakou P,et al. Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity[J]. Cancer Res,1996,56(16):3737-3742.[3] Middlemas DS,Kihl BK,Moody NM. Brain derived neurotrophic factor protects human neuroblastoma cells from DNA damaging agents[J]. J Neurooncol,1999,45(1):27-36.[4] Odate S,Nakamura K,Onishi H,et al. TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma[J]. Lung Cancer,2013,79(3):205-214.[5] Sclabas GM,Fujioka S,Schmidt C,et al. Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells[J]. Clin Cancer Res,2005,11:440-449.[6] Sakamoto Y,Kitajima Y,Edakunni G,et al. Expression of Trk tyrosine kinase receptor is a biologic marker for cell proliferation and perineural invasion of human pancreatic ductal adenocarcinoma[J]. Oncol Rep,2001,8(3):477-484.[7] Brunetto de Farias,C,Rosemberg DB,Heinen TE,et al. BDNF/ TrkB content and interaction with gastrin-releasing peptide receptor blockade in colorectal cancer[J]. Oncology,2010,79(5/6): 430-439.[8] Moon A,Won KY,Lee JY,et al. Expression of BDNF,TrkB,and p53 in early-stage squamous cell carcinoma of the uterine cervix[J]. Pathology,2011,43(5):453-458.[9] Liu M,Su YH,Chen Y. Expressions of neurotrophic factors and their receptors in prostate cancer[J]. Zhonghua Nan Ke Xue,2010,16(2): 129-131.[10] Au CW,Siu MK,Liao X,et al. Tyrosine kinase B receptor and BDNF expression in ovarian cancers-Effect on cell migration,angiogenesis and clinical outcome[J]. Cancer Lett,2009,281(2):151-161.[11] 于晓辉. TrkB介导的失巢凋亡抑制与卵巢癌的转移和耐药[D]. 上海:上海交通大学,2007.[12] Ng YK,Wong EY,Lau CP,et al. K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma cells[J]. Invest New Drugs, 2012,30(1):48-58.[13] Kupferman ME,Jiffar T,EI-Naggar A,et al. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma[J]. Oncogene,2010,29(14):2047-2059.[14] Lee J,Jiffar T,Kupferman ME. A Novel Role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma[J]. PLoS ONE,2012,7(1):e30246. [15] Lin CY,Chen HJ,Li TM,et al. beta5 integrin up-regulation in brain-derived neurotrophic factor promotes cell motility in human chondrosarcoma[J]. PLoS One,2013,8(7):e67990.[16] Zhang S,Guo D,Luo W,et al. TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells[J]. BMC Cancer,2010,10:43.[17] Liu JY,Li KX,LI AM,et al. Effects of TrkB-BDNF signaling pathway on chemoresistance and metastasis of neuroblastoma cells[J]. Chin J Pediatr Surg,2013,334(8):607-612。 [18] Li Z,Oh DY,Nakamura K,et al. Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo[J]. Cancer,2011,117(23): 5412-5422[19] Geiger TR,Song JY,Rosado A,et al. Functional characterization of human cancer-derived TRKB mutations[J]. PLoS One,2011,6(2): e16871.[20] Imam JS,Plyler JR,Bansal H,et al. Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization[J]. PLoS One,2012,7(12):e52397.[21] Cittelly DM,Dimitrova I,Howe EN,et al. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel[J]. Mol Cancer Ther,2012,11(12):2556-2565.[22] Li LX,Li SD,Yang YX,et al. Change of miRNA-200c expression in ovarian cancer and its clinical significance[J]. Acad J Sec Mil Med Univ,2011,32(6):612-617.[23] Kopp F,Oak PS,Wagner E,et al. miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression [J]. PLoS One,2012,7(11):e50469.[24] Rhein M,Schwarzer A,Yang M,et al. Leukemias induced by altered TRK-signaling are sensitive to mTOR inhibitors in preclinical models[J]. Ann Hematol,2011,90(3):283-292.[25] Cimmino F,Schulte JH,Zollo M,et al. Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness[J]. Oncogene,2009, 28(19):2015-2023.[26] Ryan J,Tivnan A,Fay J,et al. MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome[J]. Br J Cancer,2012,107(6):967-976.[27] Sun YX,Yang J,Wang PY,et al. Cisplatin regulates SH-SY5Y cell growth through downregulation of BDNF via miR-16[J]. Oncol Rep, 2013,30(5):2343-2349.[28] de Farias CB,Heinen TE,Dos Santos RP,et al. BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition[J]. Biochem Biophys Res Commun,2012,425(2):328-332.[29] Akil H,Perraud A,Mélin C,et al. Fine-tuning roles of endogenous brain-derived neurotrophic factor,TrkB and sortilin in colorectal cancer cell survival[J]. PLoS One,2011,6(9):e25097.[30] Brierley GV,Priebe IK,Purins L,et al. Serum concentrations of brain-derived neurotrophic factor (BDNF) are decreased in colorectal cancer patients[J]. Cancer Biomark,2013,13(2):67-73.。[31] Kim JM,Kim SW,Stewart R,et al. Serotonergic and BDNF genes associated with depression 1 week and 1 year after mastectomy for breast cancer[J]. Psychosom Med,2012,74(1):8-15. [32] Kowalski PJ,Paulino AF. Perineural invasion in adenoid cystic carcinoma:Its causation/promotion by brain-derived neurotrophic factor[J]. Hum Pathol,2002,33(9):933-936.[33] Deindl E. Mechanistic insights into the functional role of VEGF and its signaling partner BDNF in angiogenic tube formation[J]. Acta Physiol: Oxf,2014,doi:10.1111/apha.12299.[34] Hallden S,Sj?gren M,Hedblad B,et al. Smoking and obesity associated BDNF gene variance predicts total and cardiovascular mortality in smokers[J]. Heart,2013,99(13):949-953. |